Study of an investigational drug for advanced KRAS-pathway cancers
Part of Cancer clinical trials.
This early-phase trial tests a new investigational drug (HMPL-415S1) in people with advanced solid tumors that have limited treatment options. It aims to see how the drug is tolerated and whether it can shrink tumors, especially in cases with KRAS-pathway changes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be able to understand the study and sign consent (ICF) voluntarily.
- Your cancer must be an advanced solid tumor confirmed on a lab test (histology or cytology), and you must have no standard options left (or they didn’t work or weren’t tolerated).
- For the main expansion part: your tumor should have an activating KRAS-pathway genetic change.
- You must have at least one measurable tumor spot on scans that can be tracked (RECIST 1.1).
- Your health status must be good enough (ECOG 0–1), and your doctor must expect you to live at least 12 weeks.
- If you can become pregnant or can father a child, you and your partner must agree to reliable birth control during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, HRS-6093, for people with advanced solid tumors that have a specific genetic change called KRAS G12D. The goal is to see if the drug is safe and effective for those who have not responded to or cannot tolerate other treatments.
This trial tests a new drug (HS-10370) in combination with other cancer treatments for people with advanced solid tumors that have a specific genetic change (KRAS G12C). It's for patients who have tried standard options without success.
This trial tests a new drug called HSK39775 for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug is safe and effective for people who have few other options.
This trial tests a new drug, HRS-7172, for people with advanced solid tumors that have RAS mutations or amplifications. It aims to see if the drug is safe and effective for these cancers.
This trial tests a new drug, SHR-4506, for people with advanced cancers that have stopped responding to standard treatments or cannot be treated with standard options. It aims to see if the drug is safe and helpful.
This study tests a new drug (HSK46256) for people with advanced solid tumors that have a specific DNA repair gene change (HRR mutation). It is a first-in-human trial to find the right dose and check safety, so it may be an option if other treatments have stopped working.
Hear when a new Advanced Malignant Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.